288 related articles for article (PubMed ID: 3322752)
1. Therapeutic efficacy and pharmacokinetic properties of ciprofloxacin in intra-abdominal abscesses caused by Bacteroides fragilis and Escherichia coli.
Fu KP; Vince T; Bloom R; Gregory FJ; Hung PP
Drugs Exp Clin Res; 1987; 13(8):493-6. PubMed ID: 3322752
[TBL] [Abstract][Full Text] [Related]
2. In vivo efficacy of trovafloxacin against Bacteroides fragilis in mixed infection with either Escherichia coli or a vancomycin-resistant strain of Enterococcus faecium in an established-abscess murine model.
Stearne LE; Gyssens IC; Goessens WH; Mouton JW; Oyen WJ; van der Meer JW; Verbrugh HA
Antimicrob Agents Chemother; 2001 May; 45(5):1394-401. PubMed ID: 11302801
[TBL] [Abstract][Full Text] [Related]
3. Effect of prophylactic antibiotics upon mixed infections with Bacteroides fragilis.
Brook I
Surg Gynecol Obstet; 1987 Dec; 165(6):491-5. PubMed ID: 3317944
[TBL] [Abstract][Full Text] [Related]
4. In vivo efficacies of quinolones and clindamycin for treatment of infections with Bacteroides fragilis and/or Escherichia coli in mice: correlation with in vitro susceptibilities.
Brook I
Antimicrob Agents Chemother; 1993 May; 37(5):997-1000. PubMed ID: 8517727
[TBL] [Abstract][Full Text] [Related]
5. The role of Candida albicans in the pathogenesis of experimental fungal/bacterial peritonitis and abscess formation.
Sawyer RG; Adams RB; Rosenlof LK; May AK; Pruett TL
Am Surg; 1995 Aug; 61(8):726-31. PubMed ID: 7618816
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of rifampicin in experimental Bacteroides fragilis and Pseudomonas aeruginosa mixed infections.
Fu KP; Lasinski ER; Zoganas HC; Kimble EF; Konopka EA
J Antimicrob Chemother; 1985 May; 15(5):579-85. PubMed ID: 3924880
[TBL] [Abstract][Full Text] [Related]
7. In-vivo bactericidal activity of Sch 34343 in Bacteroides fragilis abscesses and in Bacteroides fragilis-Escherichia coli abscesses.
Wells CL; Arland LA; Simmons RL; Rotstein OD
J Antimicrob Chemother; 1985 Jun; 15 Suppl C():199-206. PubMed ID: 3897172
[TBL] [Abstract][Full Text] [Related]
8. Antibiotic penetration of experimental intra-abdominal abscesses.
Galandiuk S; Lamos J; Montgomery W; Young S; Polk HC
Am Surg; 1995 Jun; 61(6):521-5. PubMed ID: 7762902
[TBL] [Abstract][Full Text] [Related]
9. Therapeutic efficacy and pharmacokinetic properties of rifampicin in a Bacteroides fragilis intra-abdominal abscess.
Fu KP; Lasinski ER; Zoganas HC; Kimble EF; Konopka EA
J Antimicrob Chemother; 1984 Dec; 14(6):633-40. PubMed ID: 6520063
[TBL] [Abstract][Full Text] [Related]
10. Activity of ciprofloxacin in the treatment of experimental intra-abdominal abscesses in mice.
Esposito S
Clin Ther; 1989; 11(1):32-7. PubMed ID: 2720726
[TBL] [Abstract][Full Text] [Related]
11. Development of Candida albicans and C. albicans/Escherichia coli/Bacteroides fragilis intraperitoneal abscess models with demonstration of fungus-induced bacterial translocation.
Sawyer RG; Adams RB; May AK; Rosenlof LK; Pruett TL
J Med Vet Mycol; 1995; 33(1):49-52. PubMed ID: 7650578
[TBL] [Abstract][Full Text] [Related]
12. Effect of dosing and dosing frequency on the efficacy of ceftizoxime and the emergence of ceftizoxime resistance during the early development of murine abscesses caused by Bacteroides fragilis and Enterobacter cloacae mixed infection.
Stearne LE; Goessens WH; Mouton JW; Gyssens IC
Antimicrob Agents Chemother; 2007 Oct; 51(10):3605-11. PubMed ID: 17646416
[TBL] [Abstract][Full Text] [Related]
13. Pathogenicity of capsulate and non-capsulate members of Bacteroides fragilis and B. melaninogenicus groups in mixed infection with Escherichia coli and Streptococcus pyogenes.
Brook I
J Med Microbiol; 1988 Nov; 27(3):191-8. PubMed ID: 2903934
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of cefminox compared with amoxicillin/clavulanic acid as a single dose for the prevention of intra-abdominal sepsis in mice intraperitoneally infected with different strains of Escherichia coli and one strain of Bacteroides fragilis.
Huelves L; Gracia M; Del Prado G; Rodríguez-Cerrato V; Martínez-Marín C; Ponte C; Soriano F; Coronel P; Gimeno M; Blanco J
Int J Antimicrob Agents; 2006 Aug; 28(2):151-3. PubMed ID: 16815688
[No Abstract] [Full Text] [Related]
15. Levofloxacin plus metronidazole administered once daily versus moxifloxacin monotherapy against a mixed infection of Escherichia coli and Bacteroides fragilis in an in vitro pharmacodynamic model.
Hermsen ED; Hovde LB; Sprandel KA; Rodvold KA; Rotschafer JC
Antimicrob Agents Chemother; 2005 Feb; 49(2):685-9. PubMed ID: 15673752
[TBL] [Abstract][Full Text] [Related]
16. Effect of moxifloxacin versus imipenem/cilastatin treatment on the mortality of mice infected intravenously with different strains of Bacteroides fragilis and Escherichia coli.
Schaumann R; Blatz R; Beer J; Ackermann G; Rodloff AC
J Antimicrob Chemother; 2004 Feb; 53(2):318-24. PubMed ID: 14729746
[TBL] [Abstract][Full Text] [Related]
17. Therapeutic evaluation of difloxacin (A-56619) and A-56620 for experimentally induced Bacteroides fragilis-associated intra-abdominal abscess.
Thadepalli H; Gollapudi SV; Chuah SK
Antimicrob Agents Chemother; 1986 Oct; 30(4):574-6. PubMed ID: 3539011
[TBL] [Abstract][Full Text] [Related]
18. In-vitro susceptibility and in-vivo efficacy of antimicrobials in the treatment of intraabdominal sepsis in mice.
Brook I; Gillmore JD
J Antimicrob Chemother; 1993 Mar; 31(3):393-401. PubMed ID: 8486573
[TBL] [Abstract][Full Text] [Related]
19. Effect of recombinant tissue plasminogen activator on intra-abdominal abscess formation in rats with generalized peritonitis.
van Goor H; de Graaf JS; Kooi K; Sluiter WJ; Bom VJ; van der Meer J; Bleichrodt RP
J Am Coll Surg; 1994 Oct; 179(4):407-11. PubMed ID: 7921389
[TBL] [Abstract][Full Text] [Related]
20. The treatment of irradiated mice with polymicrobial infection caused by Bacteroides fragilis and Escherichia coli.
Brook I; Ledney GD
J Antimicrob Chemother; 1994 Feb; 33(2):243-52. PubMed ID: 8182005
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
